April 1, 2022 -- Regenerative medicine is taking aim at cancer and a wide range of other prevalent and rare diseases, according to the 2021 annual report of the Alliance for Regenerative Medicine (ARM).
"The exciting advancements of 2021 demonstrate that regenerative medicine is here -- and it's not slowing down," said Janet Lambert, CEO of ARM.
The #cellandgenetherapy sector disrupted the status quo in 2021 with new milestones, including the first proof-of-concept for an in vivo gene editing therapy, evidence that #CARTcell therapies compare favorably with earlier line treatments, and compelling early results that cell and gene therapies could durably treat complex, polygenic diseases.
ARM's 2021 annual report provides a comprehensive look into the investment, scientific, and clinical landscape. The 2021 report is ARM's most in-depth review of the sector to date, with never-before-released data including a deep dive into the oncology space, a look at prevalent versus #raredisease targets, an update on the #geneediting field, information on #genetherapy delivery, and more.
Read the report on ARM's site.